

**INFORMATION DISCLOSURE TO
SHAREHOLDERS OF PT BERLINA TBK
("Information Disclosure")**

with respect to

**The Purpose of Capital Increase with The Pre-Emptive Rights ("PMHMETD") and the Change of
the Article 3 of the Article of Association**

This Information Disclosure is essential to be considered by the Shareholders of the Company to make decisions that will be taken at the Extraordinary General Meeting of Shareholders of the Company ("**EGMS**"), which will be held on July 20, 2022, to comply with the provisions of the Financial Services Authority ("**FSA**") Regulation No.32/POJK.4/2015 dated December 16, 2015, concerning the Capital Increase of Public Companies with the Pre-emptive Rights *in conjunction with* the FSA Regulation No.14/POJK.04/2019 dated April 29, 2019, concerning the Amendment on the Regulation FSA Regulation No.32/POJK.04/2015 on Capital Increase of Public Companies with Pre-emptive Rights ("**POJK HMETD**") and the Change of the Article 3 of the Article of Association.

Suppose you have difficulty understanding the information that contained in this Information Disclosure or hesitant to making a decision. In that case, you should consult with a securities broker, investment manager, legal advisor, public accountant, or another professional advisor.



**PT Berlina Tbk
("Company")**

Domiciled at Bekasi Regency, West Java, Indonesia

Business Activities:

Engaged in the plastic goods industry for packaging, sheet plastic goods industry, household appliances and equipment industry (excluding furniture), plastic goods and engineering equipment industry, other plastic goods industry, other special purpose machinery industry, wholesale trading of various kinds of goods, wholesale trade on a fee basis or contract, recycling of non-metal goods, and other management consulting activities

Headquarter:

Jl. Jababeka Raya Blok E No.12-17
Kawasan Industri Jababeka, Cikarang
Bekasi, Jawa Barat 17530
Tel. (021) 8983 0160

Website: www.berlina.co.id

Email: brna.corsec@berlina.co.id

The Board of Directors and the Board of Commissioners of the Company, both individually and collectively, are fully responsible for the correctness and completeness of the information as disclosed in this Information Disclosure and after careful research, confirm that the information contained in this Information Disclosure is accurate and There are no material and relevant important facts that are not disclosed or omitted in this Information Disclosure, causing the information provided in this Information Disclosure to be untrue and / or misleading.

All information contained in this Information Disclosure is only a recommendation, subject to the approval of the EGMS; a registration statement of capital increase with the Pre-emptive Rights ("PMHMETD III") is declared effective by the FSA as well as a Prospectus to be issued in the framework of PMHMETD.

This Information Disclosure is for information only and is not intended as a public offering document of the Company in any jurisdiction where the offering or purchase of securities is a violation of the prevailing laws and regulations in the country or jurisdiction outside Indonesia's territory. Neither party can obtain Pre-Emptive Rights or new shares except based on the information contained in the Prospectus that will be issued in the framework of the PMHMETD.

This Information Disclosure is published on the IDX's Website and Company's Website on June 13, 2022

I. INFORMATION IN CONNECTION WITH CAPITAL INCREASE WITH PRE-EMPTIVE RIGHTS

The Company plans to increase its capital with the Pre-emptive Rights (“**PMHMETD III**”) to shareholders of Company on the issuance of a maximum of 244.777.500 (two hundred and forty-four million seven hundred seventy-seven thousand five hundred) new ordinary shares with a nominal value of Rp50 (fifty Rupiah) each share (“**Shares From The Exercise of Pre-Emptive Rights**”). PMHMETD III will give the Company's shareholders the right to buy the Shares From The Exercise of Pre-Emptive Rights.

The Shares From The Exercise of Pre-Emptive Rights will be issued from the Company's portfolio and listed on the Indonesia Stock Exchange (“**IDX**”) in accordance with the applicable laws and regulations, including the IDX Regulation No.I-A concerning the Listing of Shares and Equity Securities Other Than Shares Issued by the Listed Company, Attachment to the Decree of the Board of Directors of IDX No.Kep-00101/BEI/12-2021 dated December 21, 2021. Shares From the Exercise of Pre-Emptive Rights will have the same rights as other Company's shares issued by the Company prior to PMHMETD III, including the right to dividends.

In accordance with POJK HMETD, the implementation of PMHMETD III can be carried out after:

1. The Company obtained approval from the EGMS in connection with PMHMETD III;
2. The Company submits a registration statement for PMHMETD III along with its supporting documents to FSA; and
3. The registration statement in the framework of the PMHMETD III is declared effective by the FSA.

For the avoidance of doubt, the Company has the right to offer and issue part or all of the maximum number of shares that have been approved for issuance based on the resolution of the EGMS. The provisions of PMHMETD III, including the final exercise price of Pre-Emptive Rights and the final amount of Shares From the Exercise of the Pre-Emptive Rights which will be issued, will be disclosed in the Prospectus which will be published to PMHMETD III, which will be provided to the Company's entitled shareholders on time, in accordance with applicable laws and regulations.

II. ESTIMATED TIME OF IMPLEMENTATION OF CAPITAL INCREASE WITH PRE-EMPTIVE RIGHTS

The Company intends to execute and complete the capital increase with the Pre-Emptive Rights within a reasonable period of time to be carried out, by following the POJK HMETD provisions that the period between the date of EGMS approval until the effectiveness of the PMHMETD III registration statement is not more than 12 (twelve) months from the date of approval EGMS regarding PMHMETD III.

The Company's EGMS to obtain approval for the implementation of PMHMETD III which is planned to be held on July 20, 2022.

III. OUTLINE ESTIMATION OF THE USE OF PROCEEDS

The Company intends to use the proceeds of the PMHMETD III, after deducting the issuance costs, will be used for the payment / repayment of loans and / or capital expenditures and / or working capital of the Company and / or its subsidiaries.

In accordance with POJK HMETD, the implementation of PMHMETD by Public Listed Company can be done in the form of cash and / or other forms other than money and / or capital injection in the form of receivable in accordance with the provisions of POJK HMETD and Law No. 40 year 2007 concerning Limited Liability Company. In the event of the PMHMETD's implemented by capital injection in the form of receivable which is categorized as affiliated transaction as regulated in the Financial Services Authority Regulation No. 42 / POJK.04 / 2020 concerning Affiliated Transactions and Conflict of Interest on Certain Transactions (“**POJK 42/2020**”), therefore the implementation of such affiliated transaction, the parties are required to follow the provisions in POJK 42/2020.

The Final information regarding the use of proceeds will be disclosed in the Prospectus issued in the framework of PMHMETD III, which will be made available to the entitled shareholders of Company in time, in accordance with the prevailing laws and regulations.

IV. ANALYSIS ON THE IMPACT OF THE CAPITAL INCREASE ON THE FINANCIAL CONDITION OF THE COMPANY AND THE SHAREHOLDERS

IV.1. Impact on the Company's Financial Condition

The Company estimates that the plan to increase capital with the Pre-Emptive Rights will have a positive effect on the consolidated financial condition of the Company and its subsidiaries, namely, among others, improving the capital structure by decreasing loans, increasing fixed assets with capital expenditures, and increasing cash for working capital needs.

IV.2. Impact on the Shareholders

In this PMHMETD III, the Company expects as much participation as possible from the Company's shareholders to exercise the Pre-Emptive Rights that will be obtained by the shareholders. In the event that the shareholders do not exercise the Pre-Emptive Rights to be obtained, the percentage of their share ownership in the Company's shares will be diluted to a maximum of 20% of the issued and paid-up capital.

V. INFORMATION IN CONNECTION WITH THE AMENDMENT OF ARTICLE 3 OF THE ARTICLE OF ASSOCIATION

In connection with the Central Bureau of Statistics ("BPS") Regulation No. 2 of 2020 on Indonesian Standard Business Classifications ("KBLI 2020") juncto Government Regulation No. 5 of 2021 concerning the Implementation of Risk-Based Business Licensing, the Company shall adjust its Article of Association, particularly in Article 3 of the Article of Association concerning Purposes and Objectives and Business Activity in accordance with KBLI 2020.

To support customer needs in fulfilling the Regulation of the Minister of Health No. 14 of 2021 concerning Standards for Business Activities and Products in the Implementation of Health Sector Risk-Based Business Licensing, the Company intends to add KBLI for products that have been produced and supplied since 2009. There are no changes or additions to business activity in the Company.

VI. INFORMATION ABOUT EGMS

The Company intends to seek approval from shareholders, among others, in the context of implementing PMHMETD and the change of the article 3 of the Article of Association with the following schedule for the EGMS:

1. Notification to FSA regarding the planned EGMS	:	6 June 2022
2. Announcement regarding the EGMS plan	:	13 June 2022
3. Announcement of Information Disclosure regarding PMHMETD III	:	13 June 2022
4. List of Shareholders entitled to attend the EGMS (Recording Date)	:	27 June 2022
5. Invitation of EGMS	:	28 June 2022
6. Implementation of EGMS	:	20 July 2022

VII. ADDITIONAL INFORMATION

To obtain information regarding the plan to increase capital with the Pre-Emptive Rights and the change of the article 3 of the Article of Association as described above, the shareholders of the Company can contact the Company's Corporate Secretary, every day and working hour of the Company, which is 08.30 - 17.30 WIB, at the address below:

PT BERLINA TBK
Jl. Jababeka Raya Blok E No.12-17
Kawasan Industri Jababeka, Cikarang
Bekasi, Jawa Barat 17530
Tel. (021) 8983 0160

Website: www.berlina.co.id
Email: brna.corsec@berlina.co.id

Jakarta, 13 June 2022
Board of Director